Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai Pharma Unit Acquires Two Microbiome Therapies in $110 Million Deal

publication date: Oct 29, 2021

SPH SINE, a subsidiary of China's Shanghai Pharma, acquired greater China rights for two microbiome therapies from Korea's KoBioLabs in a $110 million deal. SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and  KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for China trials and commercialization. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here